Oncogene Journal

Overview
Identity
View All

publication venue for

BMI1 is a therapeutic target in recurrent medulloblastoma 2019
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. 42:293-307. 2023
Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. 41:3507-3509. 2022
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. 41:2932-2944. 2022
A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. 39:1590-1599. 2020
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. 37:1369-1385. 2018
CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. 36:606-617. 2017
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells. 35:2465-2474. 2016
BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation. 34:3063-3075. 2015
The p38-MK2-HuR pathway potentiates EGFRvIII–IL-1β-driven IL-6 secretion in glioblastoma cells. 34:2934-2942. 2015
Mammary glands exhibit molecular laterality and undergo left–right asymmetric ductal epithelial growth in MMTV-cNeu mice*. 34:2003-2010. 2015
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. 33:5319-5331. 2014
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. 33:1601-1608. 2014
SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. 31:3148-3163. 2012
Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. 31:2931-2942. 2012
Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. 31:187-199. 2012
Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. 31:93-103. 2012
Evidence for the transmission of neoplastic properties from transformed to normal human stem cells. 30:4632-4644. 2011
The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. 30:3062-3072. 2011
p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. 30:2670-2678. 2011
Still embedded together binding to membranes regulates Bcl-2 protein interactions. 29:5221-5230. 2010
Preneoplastic changes persist after IGF-IR downregulation and tumor regression. 29:4779-4786. 2010
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 28:4034-4040. 2009
Reversibility and recurrence of IGF-IR-induced mammary tumors. 28:2152-2162. 2009
Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. 27:208-217. 2008
Mutant p53: an oncogenic transcription factor. 26:2212-2219. 2007
Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. 26:1636-1644. 2007
Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression. 25:5601-5611. 2006
S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. 25:3628-3637. 2006
DNp73α protects myogenic cells from apoptosis. 25:3606-3612. 2006
Effects of hTERT on metal ion-induced genomic instability. 25:3424-3435. 2006
ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. 25:1153-1164. 2006
Erratum: Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. 25:492-492. 2006
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. 25:304-309. 2006
A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. 24:7893-7901. 2005
δEF1 repressor controls selectively p53 family members during differentiation. 24:7273-7280. 2005
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. 24:6657-6666. 2005
Williams–Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. 23:9070-9081. 2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. 23:7651-7659. 2004
ATM activity contributes to the tumor-suppressing functions of p14ARF. 23:7355-7365. 2004
Cancer stem cells in nervous system tumors. 23:7267-7273. 2004
Concepts of human leukemic development. 23:7164-7177. 2004
Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. 23:5632-5642. 2004
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. 23:5185-5192. 2004
The shortest telomeres drive karyotype evolution in transformed cells. 23:1221-1228. 2004
Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. 22:9151-9155. 2003
Radiation-induced bystander effects, carcinogenesis and models. 22:7028-7033. 2003
Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. 22:1916-1926. 2003
Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. 21:3688-3695. 2002
Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. 21:3688-3695. 2002
Monoclonal antibodies raised against Xenopus p53 interact with human p73. 21:1304-1308. 2002
The constitutive activation of the CEF-4/9E3 chemokine gene depends on C/EBPβ in v-src transformed chicken embryo fibroblasts. 20:2301-2313. 2001
Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. 20:1939-1952. 2001
Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. 20:714-725. 2001
Guest Editor. 19:6549-6549. 2000
Correction: Corrigendum. 19:5039-5039. 2000
The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades.. 19:5039. 2000
Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. 19:329-336. 2000
Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. 18:3520-3528. 1999
Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. 18:2643-2649. 1999
Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. 18:1663-1676. 1999
Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. 18:783-788. 1999
Inhibition of RNA polymerase II as a trigger for the p53 response. 18:583-592. 1999
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. 18:477-485. 1999
Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. 17:1923-1930. 1998
Up-regulation of CIR1/CROC1 expression upon cell immortalization and in tumor-derived human cell lines. 17:1321-1326. 1998
At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes. 17:565-576. 1998
Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. 17:545-555. 1998
The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. 16:301-310. 1998
Induction of Mdm2 and enhancement of cell survival by bFGF. 15:2717-2725. 1997
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. 15:1513-1525. 1997
Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. 15:607-611. 1997
Transcriptional and post-transcriptional regulation of κB-controlled genes by pp60v-src. 15:29-43. 1997
The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades.. 13:1323-1333. 1996
Testing NF-kappa B1-p50 antibody specificity using knockout mice.. 13:445-446. 1996
Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.. 12:507-513. 1996
The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF-kappa B to the MHC class I enhancer in transformed cells.. 12:143-151. 1996
Telomerase activity in normal and malignant murine tissues.. 11:893-898. 1995
Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells.. 10:731-737. 1995
Induction of genomic instability in SV40 transformed human cells: sufficiency of the N-terminal 147 amino acids of large T antigen and role of pRB and p53.. 9:2943-2950. 1994
Activation of human immunodeficiency virus 1 gene expression by the src oncoprotein.. 9:2399-2403. 1994
Isolation of two novel ras genes in Dictyostelium discoideum; evidence for a complex, developmentally regulated ras gene subfamily.. 9:501-508. 1994
PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.. 8:3037-3042. 1993
Characterization of a third ras gene, rasB, that is expressed throughout the growth and development of Dictyostelium discoideum.. 8:1041-1047. 1993
Reversion of middle T antigen-transformed Rat-2 cells by Krev-1: implications for the role of p21c-ras in polyomavirus-mediated transformation.. 7:1687-1698. 1992
Complex expression pattern of the CEF-4 cytokine in transformed and mitogenically stimulated cells.. 6:1825-1833. 1991

has subject area

1103 Clinical Sciences (FoR)
1112 Oncology and Carcinogenesis (FoR)
Oncology & Carcinogenesis (Science Metrix)